Clinical trial · Interventional
To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects
A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect of JMKX001899 on the QTc Interval in Healthy Subjects
NCT06473948CI-TRIAL-00078214unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study to assess the effect of JMKX001899 on QTc interval in healthy volunteers
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor, Adult | Adult Solid Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| JMKX001899 | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Cohort 1
- description
- Participants will receive JMKX001899 500 once on Day 1
- interventionNames
- Drug: JMKX001899
- Drug: Placebo
- type
- EXPERIMENTAL
- label
- Cohort 2
- description
- Participants will receive JMKX001899 750 once on Day 1
- interventionNames
- Drug: JMKX001899
- Drug: Placebo
- type
- EXPERIMENTAL
- label
- Cohort 3
- description
- Participants will receive JMKX001899 1000 once on Day 1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: 1. Healthy, adult, male or female 18-45 years of age, inclusive. 2. Body mass index (BMI) between 19 and 28 kg/m2 (inclusive) and weight at least 50 kg. 3. Participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study. Exclusion Criteria: 1. Patients with a history of clinically significant diseases including, but not limited to, gastrointestinal, renal, liver, neurological, hematological, endocrine, neoplastic, pulmonary, immune, psychiatric, or cardiovascular and cerebrovascular diseases, epilepsy, bipolar disorder/mania, intraocular hypertension, or acute angle-closure glaucoma. 2. Female subjects with a positive pregnancy test or lactating. 3. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) or Treponema pallidum（TP-Ab）
References
Publications (0)
Data not yet available
No reference posted for this study.